The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pet Recombinant Vaccine Market Research Report 2025
Synopsis
Vaccines prepared at the genetic level for pet vaccination are called pet recombinant vaccines.
The global Pet Recombinant Vaccine market was valued at US$ 490.2 million in 2023 and is anticipated to reach US$ 711.8 million by 2030, witnessing a CAGR of 5.6% during the forecast period 2024-2030.
Pet medical care is the second largest segment in pet industry. In the UK, annual spending on veterinary and other pet services has risen from £2.6bn in 2015 to £4bn in 2021, a 54% increase in just six years. According to Vetnosis, the value of the global animal health industry will increase by 12% to $38.3 billion in 2021. White Paper on China's Pet Healthy Consumption of JD shows that in 2023, there are 13.09 million pets entering middle age and old age. And pet aging is expected to be seen in the next few years. Changes in the age structure of pets will further bring about the development of the pet medical industry. According to the data of the 2022 China Pet Medical Industry White Paper, from the perspective of market size, the scale of China's pet medical market is about ¥67.5 billion, accounting for about 22.5% of the entire pet industry. From the perspective of hospital operation time, pet hospitals within 5 years accounted for about 73%. About 11% of the pet hospitals have been in operation for more than 10 years. From the perspective of hospital turnover, nearly 40% of the hospitals have increased their annual turnover year-on-year, and the growth rate is mainly within 378%.
This report aims to provide a comprehensive presentation of the global market for Pet Recombinant Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pet Recombinant Vaccine.
Report Scope
The Pet Recombinant Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pet Recombinant Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pet Recombinant Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer Healthcare
Vetoquinol S.A
Boehringer Ingelheim
Ceva
Eli Lilly
Heska
Merck Animal Health
Merial (Sanofi)
Virbac
Pfizer
Segment by Type
Genetically Engineered Vaccines
Genetically Recombinant Vaccines
Transgenic Plant Vaccines
DNA Vaccines
Segment by Application
Dog
Cat
Dird
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pet Recombinant Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pet Recombinant Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Vaccines prepared at the genetic level for pet vaccination are called pet recombinant vaccines.
The global Pet Recombinant Vaccine market was valued at US$ 490.2 million in 2023 and is anticipated to reach US$ 711.8 million by 2030, witnessing a CAGR of 5.6% during the forecast period 2024-2030.
Pet medical care is the second largest segment in pet industry. In the UK, annual spending on veterinary and other pet services has risen from £2.6bn in 2015 to £4bn in 2021, a 54% increase in just six years. According to Vetnosis, the value of the global animal health industry will increase by 12% to $38.3 billion in 2021. White Paper on China's Pet Healthy Consumption of JD shows that in 2023, there are 13.09 million pets entering middle age and old age. And pet aging is expected to be seen in the next few years. Changes in the age structure of pets will further bring about the development of the pet medical industry. According to the data of the 2022 China Pet Medical Industry White Paper, from the perspective of market size, the scale of China's pet medical market is about ¥67.5 billion, accounting for about 22.5% of the entire pet industry. From the perspective of hospital operation time, pet hospitals within 5 years accounted for about 73%. About 11% of the pet hospitals have been in operation for more than 10 years. From the perspective of hospital turnover, nearly 40% of the hospitals have increased their annual turnover year-on-year, and the growth rate is mainly within 378%.
This report aims to provide a comprehensive presentation of the global market for Pet Recombinant Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pet Recombinant Vaccine.
Report Scope
The Pet Recombinant Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pet Recombinant Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pet Recombinant Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer Healthcare
Vetoquinol S.A
Boehringer Ingelheim
Ceva
Eli Lilly
Heska
Merck Animal Health
Merial (Sanofi)
Virbac
Pfizer
Segment by Type
Genetically Engineered Vaccines
Genetically Recombinant Vaccines
Transgenic Plant Vaccines
DNA Vaccines
Segment by Application
Dog
Cat
Dird
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pet Recombinant Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pet Recombinant Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Pet Recombinant Vaccine Market Overview
1.1 Product Overview and Scope of Pet Recombinant Vaccine
1.2 Pet Recombinant Vaccine Segment by Type
1.2.1 Global Pet Recombinant Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Genetically Engineered Vaccines
1.2.3 Genetically Recombinant Vaccines
1.2.4 Transgenic Plant Vaccines
1.2.5 DNA Vaccines
1.3 Pet Recombinant Vaccine Segment by Application
1.3.1 Global Pet Recombinant Vaccine Market Value by Application: (2024-2030)
1.3.2 Dog
1.3.3 Cat
1.3.4 Dird
1.3.5 Others
1.4 Global Pet Recombinant Vaccine Market Size Estimates and Forecasts
1.4.1 Global Pet Recombinant Vaccine Revenue 2019-2030
1.4.2 Global Pet Recombinant Vaccine Sales 2019-2030
1.4.3 Global Pet Recombinant Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Pet Recombinant Vaccine Market Competition by Manufacturers
2.1 Global Pet Recombinant Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Pet Recombinant Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Pet Recombinant Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Pet Recombinant Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Pet Recombinant Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pet Recombinant Vaccine, Product Type & Application
2.7 Pet Recombinant Vaccine Market Competitive Situation and Trends
2.7.1 Pet Recombinant Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Pet Recombinant Vaccine Players Market Share by Revenue
2.7.3 Global Pet Recombinant Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Pet Recombinant Vaccine Retrospective Market Scenario by Region
3.1 Global Pet Recombinant Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Pet Recombinant Vaccine Global Pet Recombinant Vaccine Sales by Region: 2019-2030
3.2.1 Global Pet Recombinant Vaccine Sales by Region: 2019-2024
3.2.2 Global Pet Recombinant Vaccine Sales by Region: 2025-2030
3.3 Global Pet Recombinant Vaccine Global Pet Recombinant Vaccine Revenue by Region: 2019-2030
3.3.1 Global Pet Recombinant Vaccine Revenue by Region: 2019-2024
3.3.2 Global Pet Recombinant Vaccine Revenue by Region: 2025-2030
3.4 North America Pet Recombinant Vaccine Market Facts & Figures by Country
3.4.1 North America Pet Recombinant Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Pet Recombinant Vaccine Sales by Country (2019-2030)
3.4.3 North America Pet Recombinant Vaccine Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Pet Recombinant Vaccine Market Facts & Figures by Country
3.5.1 Europe Pet Recombinant Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Pet Recombinant Vaccine Sales by Country (2019-2030)
3.5.3 Europe Pet Recombinant Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pet Recombinant Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Pet Recombinant Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Pet Recombinant Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Pet Recombinant Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Pet Recombinant Vaccine Market Facts & Figures by Country
3.7.1 Latin America Pet Recombinant Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Pet Recombinant Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Pet Recombinant Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Pet Recombinant Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Pet Recombinant Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Pet Recombinant Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Pet Recombinant Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Pet Recombinant Vaccine Sales by Type (2019-2030)
4.1.1 Global Pet Recombinant Vaccine Sales by Type (2019-2024)
4.1.2 Global Pet Recombinant Vaccine Sales by Type (2025-2030)
4.1.3 Global Pet Recombinant Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Pet Recombinant Vaccine Revenue by Type (2019-2030)
4.2.1 Global Pet Recombinant Vaccine Revenue by Type (2019-2024)
4.2.2 Global Pet Recombinant Vaccine Revenue by Type (2025-2030)
4.2.3 Global Pet Recombinant Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Pet Recombinant Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Pet Recombinant Vaccine Sales by Application (2019-2030)
5.1.1 Global Pet Recombinant Vaccine Sales by Application (2019-2024)
5.1.2 Global Pet Recombinant Vaccine Sales by Application (2025-2030)
5.1.3 Global Pet Recombinant Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Pet Recombinant Vaccine Revenue by Application (2019-2030)
5.2.1 Global Pet Recombinant Vaccine Revenue by Application (2019-2024)
5.2.2 Global Pet Recombinant Vaccine Revenue by Application (2025-2030)
5.2.3 Global Pet Recombinant Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Pet Recombinant Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bayer Healthcare
6.1.1 Bayer Healthcare Corporation Information
6.1.2 Bayer Healthcare Description and Business Overview
6.1.3 Bayer Healthcare Pet Recombinant Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bayer Healthcare Pet Recombinant Vaccine Product Portfolio
6.1.5 Bayer Healthcare Recent Developments/Updates
6.2 Vetoquinol S.A
6.2.1 Vetoquinol S.A Corporation Information
6.2.2 Vetoquinol S.A Description and Business Overview
6.2.3 Vetoquinol S.A Pet Recombinant Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Vetoquinol S.A Pet Recombinant Vaccine Product Portfolio
6.2.5 Vetoquinol S.A Recent Developments/Updates
6.3 Boehringer Ingelheim
6.3.1 Boehringer Ingelheim Corporation Information
6.3.2 Boehringer Ingelheim Description and Business Overview
6.3.3 Boehringer Ingelheim Pet Recombinant Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Boehringer Ingelheim Pet Recombinant Vaccine Product Portfolio
6.3.5 Boehringer Ingelheim Recent Developments/Updates
6.4 Ceva
6.4.1 Ceva Corporation Information
6.4.2 Ceva Description and Business Overview
6.4.3 Ceva Pet Recombinant Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Ceva Pet Recombinant Vaccine Product Portfolio
6.4.5 Ceva Recent Developments/Updates
6.5 Eli Lilly
6.5.1 Eli Lilly Corporation Information
6.5.2 Eli Lilly Description and Business Overview
6.5.3 Eli Lilly Pet Recombinant Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Eli Lilly Pet Recombinant Vaccine Product Portfolio
6.5.5 Eli Lilly Recent Developments/Updates
6.6 Heska
6.6.1 Heska Corporation Information
6.6.2 Heska Description and Business Overview
6.6.3 Heska Pet Recombinant Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Heska Pet Recombinant Vaccine Product Portfolio
6.6.5 Heska Recent Developments/Updates
6.7 Merck Animal Health
6.6.1 Merck Animal Health Corporation Information
6.6.2 Merck Animal Health Description and Business Overview
6.6.3 Merck Animal Health Pet Recombinant Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merck Animal Health Pet Recombinant Vaccine Product Portfolio
6.7.5 Merck Animal Health Recent Developments/Updates
6.8 Merial (Sanofi)
6.8.1 Merial (Sanofi) Corporation Information
6.8.2 Merial (Sanofi) Description and Business Overview
6.8.3 Merial (Sanofi) Pet Recombinant Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Merial (Sanofi) Pet Recombinant Vaccine Product Portfolio
6.8.5 Merial (Sanofi) Recent Developments/Updates
6.9 Virbac
6.9.1 Virbac Corporation Information
6.9.2 Virbac Description and Business Overview
6.9.3 Virbac Pet Recombinant Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Virbac Pet Recombinant Vaccine Product Portfolio
6.9.5 Virbac Recent Developments/Updates
6.10 Pfizer
6.10.1 Pfizer Corporation Information
6.10.2 Pfizer Description and Business Overview
6.10.3 Pfizer Pet Recombinant Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Pfizer Pet Recombinant Vaccine Product Portfolio
6.10.5 Pfizer Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pet Recombinant Vaccine Industry Chain Analysis
7.2 Pet Recombinant Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pet Recombinant Vaccine Production Mode & Process
7.4 Pet Recombinant Vaccine Sales and Marketing
7.4.1 Pet Recombinant Vaccine Sales Channels
7.4.2 Pet Recombinant Vaccine Distributors
7.5 Pet Recombinant Vaccine Customers
8 Pet Recombinant Vaccine Market Dynamics
8.1 Pet Recombinant Vaccine Industry Trends
8.2 Pet Recombinant Vaccine Market Drivers
8.3 Pet Recombinant Vaccine Market Challenges
8.4 Pet Recombinant Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Pet Recombinant Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Pet Recombinant Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Pet Recombinant Vaccine Market Competitive Situation by Manufacturers in 2023
Table 4. Global Pet Recombinant Vaccine Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Pet Recombinant Vaccine Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Pet Recombinant Vaccine Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Pet Recombinant Vaccine Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Pet Recombinant Vaccine Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Pet Recombinant Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Pet Recombinant Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Pet Recombinant Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Pet Recombinant Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Pet Recombinant Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pet Recombinant Vaccine as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Pet Recombinant Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Pet Recombinant Vaccine Sales by Region (2019-2024) & (K Units)
Table 18. Global Pet Recombinant Vaccine Sales Market Share by Region (2019-2024)
Table 19. Global Pet Recombinant Vaccine Sales by Region (2025-2030) & (K Units)
Table 20. Global Pet Recombinant Vaccine Sales Market Share by Region (2025-2030)
Table 21. Global Pet Recombinant Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Pet Recombinant Vaccine Revenue Market Share by Region (2019-2024)
Table 23. Global Pet Recombinant Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Pet Recombinant Vaccine Revenue Market Share by Region (2025-2030)
Table 25. North America Pet Recombinant Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Pet Recombinant Vaccine Sales by Country (2019-2024) & (K Units)
Table 27. North America Pet Recombinant Vaccine Sales by Country (2025-2030) & (K Units)
Table 28. North America Pet Recombinant Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Pet Recombinant Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Pet Recombinant Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Pet Recombinant Vaccine Sales by Country (2019-2024) & (K Units)
Table 32. Europe Pet Recombinant Vaccine Sales by Country (2025-2030) & (K Units)
Table 33. Europe Pet Recombinant Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Pet Recombinant Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Pet Recombinant Vaccine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Pet Recombinant Vaccine Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Pet Recombinant Vaccine Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Pet Recombinant Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Pet Recombinant Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Pet Recombinant Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Pet Recombinant Vaccine Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Pet Recombinant Vaccine Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Pet Recombinant Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Pet Recombinant Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Pet Recombinant Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Pet Recombinant Vaccine Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Pet Recombinant Vaccine Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Pet Recombinant Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Pet Recombinant Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Pet Recombinant Vaccine Sales (K Units) by Type (2019-2024)
Table 51. Global Pet Recombinant Vaccine Sales (K Units) by Type (2025-2030)
Table 52. Global Pet Recombinant Vaccine Sales Market Share by Type (2019-2024)
Table 53. Global Pet Recombinant Vaccine Sales Market Share by Type (2025-2030)
Table 54. Global Pet Recombinant Vaccine Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Pet Recombinant Vaccine Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Pet Recombinant Vaccine Revenue Market Share by Type (2019-2024)
Table 57. Global Pet Recombinant Vaccine Revenue Market Share by Type (2025-2030)
Table 58. Global Pet Recombinant Vaccine Price (US$/Unit) by Type (2019-2024)
Table 59. Global Pet Recombinant Vaccine Price (US$/Unit) by Type (2025-2030)
Table 60. Global Pet Recombinant Vaccine Sales (K Units) by Application (2019-2024)
Table 61. Global Pet Recombinant Vaccine Sales (K Units) by Application (2025-2030)
Table 62. Global Pet Recombinant Vaccine Sales Market Share by Application (2019-2024)
Table 63. Global Pet Recombinant Vaccine Sales Market Share by Application (2025-2030)
Table 64. Global Pet Recombinant Vaccine Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Pet Recombinant Vaccine Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Pet Recombinant Vaccine Revenue Market Share by Application (2019-2024)
Table 67. Global Pet Recombinant Vaccine Revenue Market Share by Application (2025-2030)
Table 68. Global Pet Recombinant Vaccine Price (US$/Unit) by Application (2019-2024)
Table 69. Global Pet Recombinant Vaccine Price (US$/Unit) by Application (2025-2030)
Table 70. Bayer Healthcare Corporation Information
Table 71. Bayer Healthcare Description and Business Overview
Table 72. Bayer Healthcare Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Bayer Healthcare Pet Recombinant Vaccine Product
Table 74. Bayer Healthcare Recent Developments/Updates
Table 75. Vetoquinol S.A Corporation Information
Table 76. Vetoquinol S.A Description and Business Overview
Table 77. Vetoquinol S.A Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Vetoquinol S.A Pet Recombinant Vaccine Product
Table 79. Vetoquinol S.A Recent Developments/Updates
Table 80. Boehringer Ingelheim Corporation Information
Table 81. Boehringer Ingelheim Description and Business Overview
Table 82. Boehringer Ingelheim Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Boehringer Ingelheim Pet Recombinant Vaccine Product
Table 84. Boehringer Ingelheim Recent Developments/Updates
Table 85. Ceva Corporation Information
Table 86. Ceva Description and Business Overview
Table 87. Ceva Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Ceva Pet Recombinant Vaccine Product
Table 89. Ceva Recent Developments/Updates
Table 90. Eli Lilly Corporation Information
Table 91. Eli Lilly Description and Business Overview
Table 92. Eli Lilly Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Eli Lilly Pet Recombinant Vaccine Product
Table 94. Eli Lilly Recent Developments/Updates
Table 95. Heska Corporation Information
Table 96. Heska Description and Business Overview
Table 97. Heska Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Heska Pet Recombinant Vaccine Product
Table 99. Heska Recent Developments/Updates
Table 100. Merck Animal Health Corporation Information
Table 101. Merck Animal Health Description and Business Overview
Table 102. Merck Animal Health Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Merck Animal Health Pet Recombinant Vaccine Product
Table 104. Merck Animal Health Recent Developments/Updates
Table 105. Merial (Sanofi) Corporation Information
Table 106. Merial (Sanofi) Description and Business Overview
Table 107. Merial (Sanofi) Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Merial (Sanofi) Pet Recombinant Vaccine Product
Table 109. Merial (Sanofi) Recent Developments/Updates
Table 110. Virbac Corporation Information
Table 111. Virbac Description and Business Overview
Table 112. Virbac Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Virbac Pet Recombinant Vaccine Product
Table 114. Virbac Recent Developments/Updates
Table 115. Pfizer Corporation Information
Table 116. Pfizer Description and Business Overview
Table 117. Pfizer Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Pfizer Pet Recombinant Vaccine Product
Table 119. Pfizer Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Pet Recombinant Vaccine Distributors List
Table 123. Pet Recombinant Vaccine Customers List
Table 124. Pet Recombinant Vaccine Market Trends
Table 125. Pet Recombinant Vaccine Market Drivers
Table 126. Pet Recombinant Vaccine Market Challenges
Table 127. Pet Recombinant Vaccine Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Pet Recombinant Vaccine
Figure 2. Global Pet Recombinant Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Pet Recombinant Vaccine Market Share by Type in 2023 & 2030
Figure 4. Genetically Engineered Vaccines Product Picture
Figure 5. Genetically Recombinant Vaccines Product Picture
Figure 6. Transgenic Plant Vaccines Product Picture
Figure 7. DNA Vaccines Product Picture
Figure 8. Global Pet Recombinant Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global Pet Recombinant Vaccine Market Share by Application in 2023 & 2030
Figure 10. Dog
Figure 11. Cat
Figure 12. Dird
Figure 13. Others
Figure 14. Global Pet Recombinant Vaccine Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Pet Recombinant Vaccine Market Size (2019-2030) & (US$ Million)
Figure 16. Global Pet Recombinant Vaccine Sales (2019-2030) & (K Units)
Figure 17. Global Pet Recombinant Vaccine Average Price (US$/Unit) & (2019-2030)
Figure 18. Pet Recombinant Vaccine Report Years Considered
Figure 19. Pet Recombinant Vaccine Sales Share by Manufacturers in 2023
Figure 20. Global Pet Recombinant Vaccine Revenue Share by Manufacturers in 2023
Figure 21. The Global 5 and 10 Largest Pet Recombinant Vaccine Players: Market Share by Revenue in 2023
Figure 22. Pet Recombinant Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 23. Global Pet Recombinant Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 24. North America Pet Recombinant Vaccine Sales Market Share by Country (2019-2030)
Figure 25. North America Pet Recombinant Vaccine Revenue Market Share by Country (2019-2030)
Figure 26. United States Pet Recombinant Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. Canada Pet Recombinant Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. Europe Pet Recombinant Vaccine Sales Market Share by Country (2019-2030)
Figure 29. Europe Pet Recombinant Vaccine Revenue Market Share by Country (2019-2030)
Figure 30. Germany Pet Recombinant Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. France Pet Recombinant Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. U.K. Pet Recombinant Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Italy Pet Recombinant Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Russia Pet Recombinant Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Asia Pacific Pet Recombinant Vaccine Sales Market Share by Region (2019-2030)
Figure 36. Asia Pacific Pet Recombinant Vaccine Revenue Market Share by Region (2019-2030)
Figure 37. China Pet Recombinant Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Japan Pet Recombinant Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. South Korea Pet Recombinant Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. India Pet Recombinant Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Australia Pet Recombinant Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. China Taiwan Pet Recombinant Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Indonesia Pet Recombinant Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Thailand Pet Recombinant Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Malaysia Pet Recombinant Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Latin America Pet Recombinant Vaccine Sales Market Share by Country (2019-2030)
Figure 47. Latin America Pet Recombinant Vaccine Revenue Market Share by Country (2019-2030)
Figure 48. Mexico Pet Recombinant Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Brazil Pet Recombinant Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Argentina Pet Recombinant Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Middle East & Africa Pet Recombinant Vaccine Sales Market Share by Country (2019-2030)
Figure 52. Middle East & Africa Pet Recombinant Vaccine Revenue Market Share by Country (2019-2030)
Figure 53. Turkey Pet Recombinant Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Saudi Arabia Pet Recombinant Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. UAE Pet Recombinant Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 56. Global Sales Market Share of Pet Recombinant Vaccine by Type (2019-2030)
Figure 57. Global Revenue Market Share of Pet Recombinant Vaccine by Type (2019-2030)
Figure 58. Global Pet Recombinant Vaccine Price (US$/Unit) by Type (2019-2030)
Figure 59. Global Sales Market Share of Pet Recombinant Vaccine by Application (2019-2030)
Figure 60. Global Revenue Market Share of Pet Recombinant Vaccine by Application (2019-2030)
Figure 61. Global Pet Recombinant Vaccine Price (US$/Unit) by Application (2019-2030)
Figure 62. Pet Recombinant Vaccine Value Chain
Figure 63. Pet Recombinant Vaccine Production Process
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Distributors Profiles
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
